BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.

The African Pharmaceutical Market is projected to grow at an impressive CAGR of 6-8% by 2029, driven by a booming population, ...

Read about BioNTech SE ADR (BNTX:XNAS) stock and today's latest news and financial updates.